After flexing its antibody-drug conjugate (ADC) bona fides at ASCO last year, AbbVie is advancing its solid tumor ambitions ...

Add Sanofi to the list of drugmakers committing billions to bolster their operations in the United States as President Donald ...

So far in his second term, President Donald Trump has been trying to coerce international corporations to bolster their ...

Workers at AbbVie’s manufacturing facility in Carrigtwohill, Ireland—one of six plants the Illinois drugmaker runs in the ...

Despite holding the lead with its complement inhibitor Syfovre, Apellis Pharmaceuticals is discovering that the geographic ...

For investors in gene therapy biotech bluebird bio, a wait-and-see approach toward a proposed acquisition has paid off. | For ...

Famar, a portfolio company of the private equity firm of MidEuropa, is set to acquire a sterile manufacturing facility in ...

A new promo for Roche’s blockbuster hemophilia A drug Hemlibra focuses less on those with the genetic bleeding disorder and ...

Thanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

Bluebird bio shareholders have dragged their feet in tendering shares as part of the company’s sale process, prompting buyers ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast ...